Chantal Fridle1, Michael Medinger2, Matthias C Wilk3, Katja Seipel4, Jakob Passweg2, Markus G Manz3, Thomas Pabst1. 1. a Department of Medical Oncology , University Hospital Berne and University of Berne , Berne , Switzerland. 2. b Department of Hematology , University Hospital , Basel , Switzerland. 3. c Division of Hematology , University Hospital Zurich and University of Zurich , Zurich , Switzerland. 4. d Department of Clinical Research , University of Berne , Berne , Switzerland.
Abstract
BACKGROUND: The prognosis for relapsing AML patients is disappointing and the preferred salvage chemotherapy is unclear. Among other regimens, cladribine, cytarabine, and idarubicin (CLA-Ida) is used. METHODS: We analyzed relapsing AML patients receiving CLA-Ida chemotherapy between July 2012 and April 2015 at three academic centers in Switzerland. RESULTS: Thirty-four patients underwent at least one cycle of CLA-Ida chemotherapy, with 6 patients having two cycles. Treatment-related mortality was 5.9% (2/34 patients). Eighteen patients (52.9%) achieved a complete remission (CR2), and 16 (47.1%) received subsequent allogeneic transplantation, with 8 (23.5%) of these patients remaining in complete remission after a median follow-up of 6 months. In contrast, all 16 patients not achieving CR2 died within 12 months after relapse due to progressive disease. CONCLUSION: Our data suggest a promising rate of complete remission following CLA-Ida salvage treatment in relapsing AML patients enabling a substantial proportion of such patients to proceed to allogeneic transplantation.
BACKGROUND: The prognosis for relapsing AMLpatients is disappointing and the preferred salvage chemotherapy is unclear. Among other regimens, cladribine, cytarabine, and idarubicin (CLA-Ida) is used. METHODS: We analyzed relapsing AMLpatients receiving CLA-Ida chemotherapy between July 2012 and April 2015 at three academic centers in Switzerland. RESULTS: Thirty-four patients underwent at least one cycle of CLA-Ida chemotherapy, with 6 patients having two cycles. Treatment-related mortality was 5.9% (2/34 patients). Eighteen patients (52.9%) achieved a complete remission (CR2), and 16 (47.1%) received subsequent allogeneic transplantation, with 8 (23.5%) of these patients remaining in complete remission after a median follow-up of 6 months. In contrast, all 16 patients not achieving CR2 died within 12 months after relapse due to progressive disease. CONCLUSION: Our data suggest a promising rate of complete remission following CLA-Ida salvage treatment in relapsing AMLpatients enabling a substantial proportion of such patients to proceed to allogeneic transplantation.
Authors: Kirsten M Knecht; Olga Buzovetsky; Constanze Schneider; Dominique Thomas; Vishok Srikanth; Lars Kaderali; Florentina Tofoleanu; Krystle Reiss; Nerea Ferreirós; Gerd Geisslinger; Victor S Batista; Xiaoyun Ji; Jindrich Cinatl; Oliver T Keppler; Yong Xiong Journal: Proc Natl Acad Sci U S A Date: 2018-10-10 Impact factor: 11.205
Authors: Julia N Artsemyeva; Ekaterina A Remeeva; Tatiana N Buravskaya; Irina D Konstantinova; Roman S Esipov; Anatoly I Miroshnikov; Natalia M Litvinko; Igor A Mikhailopulo Journal: Beilstein J Org Chem Date: 2020-10-22 Impact factor: 2.883